Moonsue Lee - InnoTherapy Founder CEO

246960 Stock  KRW 8,370  340.00  3.90%   

CEO

Moonsue Lee is Founder CEO of InnoTherapy
Age 49
Phone82 2 6959 1338
Webhttp://www.innotherapy.com

InnoTherapy Management Efficiency

The company has return on total asset (ROA) of (0.1318) % which means that it has lost $0.1318 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (66.3433) %, meaning that it generated substantial loss on money invested by shareholders. InnoTherapy's management efficiency ratios could be used to measure how well InnoTherapy manages its routine affairs as well as how well it operates its assets and liabilities.
InnoTherapy has accumulated 17.17 B in total debt with debt to equity ratio (D/E) of 0.56, which is about average as compared to similar companies. InnoTherapy has a current ratio of 6.62, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist InnoTherapy until it has trouble settling it off, either with new capital or with free cash flow. So, InnoTherapy's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like InnoTherapy sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for InnoTherapy to invest in growth at high rates of return. When we think about InnoTherapy's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

CEO Age

Yun LeeDaihan Pharmaceutical CoLtd
68
Seong OhAminologics CoLtd
57
Jang OhAminologics CoLtd
60
InnoTherapy, Inc., engages in the development and sale of medical sealant products in South Korea. The company was founded in 2010 and is headquartered in Seoul, South Korea. InnoTherapy is traded on Korean Securities Dealers Automated Quotations in South Korea. InnoTherapy (246960) is traded on KOSDAQ in Korea and employs 26 people.

Management Performance

InnoTherapy Leadership Team

Elected by the shareholders, the InnoTherapy's board of directors comprises two types of representatives: InnoTherapy inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InnoTherapy. The board's role is to monitor InnoTherapy's management team and ensure that shareholders' interests are well served. InnoTherapy's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InnoTherapy's outside directors are responsible for providing unbiased perspectives on the board's policies.
HaeShin Lee, Founder CTO
Chang Kim, I America
Mi Koh, Head Center
Moonsue Lee, Founder CEO
In Moon, COO CFO

InnoTherapy Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is InnoTherapy a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with InnoTherapy

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if InnoTherapy position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in InnoTherapy will appreciate offsetting losses from the drop in the long position's value.

Moving together with InnoTherapy Stock

  0.74102940 Kolon Life SciencePairCorr
  0.63074430 Aminologics CoLtdPairCorr
  0.81047920 HLB PharmaceuticalPairCorr

Moving against InnoTherapy Stock

  0.59216080 JETEMAPairCorr
  0.49106190 High Tech PharmPairCorr
The ability to find closely correlated positions to InnoTherapy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace InnoTherapy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back InnoTherapy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling InnoTherapy to buy it.
The correlation of InnoTherapy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as InnoTherapy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if InnoTherapy moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for InnoTherapy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in InnoTherapy Stock

InnoTherapy financial ratios help investors to determine whether InnoTherapy Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in InnoTherapy with respect to the benefits of owning InnoTherapy security.